Poly (ADP-ribose) polymerase inhibitor: A new horizon in advanced prostate cancer treatment

被引：0

作者：

Kang, Minyong ^{[1
,2
,3
]}

Jeon, Seong Soo ^{[1
]}

机构：

[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Urol, Seoul, South Korea

[2] Sungkyunkwan Univ, SAIHST, Dept Hlth Sci & Technol, Seoul, South Korea

[3] Samsung Med Ctr, Samsung Genome Inst, Seoul, South Korea

来源：

INVESTIGATIVE AND CLINICAL UROLOGY | 2023年 / 64卷 / 05期

基金：

新加坡国家研究基金会;

关键词：

D O I：

10.4111/icu.20230185

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：419 / 421

页数：3

共 10 条

[1] Agarwal N, 2023, J CLIN ONCOL, V41
[2] Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer
Asim, Mohammad
Tarish, Firas
Zecchini, Heather I.
Sanjiv, Kumar
Gelali, Eleni
Massie, Charles E.
Baridi, Ajoeb
Warren, Anne Y.
Zhao, Wanfeng
Ogris, Christoph
McDuffus, Leigh-Anne
Mascalchi, Patrice
Shaw, Greg
Dev, Harveer
Wadhwa, Karan
Wijnhoven, Paul
Forment, Josep V.
Lyons, Scott R.
Lynch, Andy G.
O'Neill, Cormac
Zecchini, Vincent R.
Rennie, Paul S.
Baniahmad, Aria
Tavare, Simon
Mills, Ian G.
Galanty, Yaron
Crosetto, Nicola
Schultz, Niklas
Neal, David
Helleday, Thomas
[J]. NATURE COMMUNICATIONS, 2017, 8
[3] Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations.
Chi, Kim N.
Rathkopf, Dana E.
Smith, Matthew Raymond
Efstathiou, Eleni
Attard, Gerhardt
Olmos, David
Lee, Ji Youl
Small, Eric Jay
Gomes, Andrea Juliana
Roubaud, Guilhem
Saad, Marniza
Zurawski, Bogdan
Sakalo, Valerii
Mason, Gary
del Corral, Adam
Wang, George C.
Wu, Daphne
Diorio, Brooke
Lopez-Gitlitz, Angela Mennicke
Sandhu, Shahneen Kaur
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[4] Clarke Noel W, 2022, NEJM Evid, V1, pEVIDoa2200043, DOI 10.1056/EVIDoa2200043
[5] Clarke NW, 2023, J Clin Oncol, V41, pLBA16, DOI [DOI 10.1200/JCO.2023.41.6, 10.1200/JCO.2023.41.6_suppl.LBA16, DOI 10.1200/JCO.2023.41.6_SUPPL.LBA16]
[6] Olaparib for Metastatic Castration-Resistant Prostate Cancer
de Bono, J.
Mateo, J.
Fizazi, K.
Saad, F.
Shore, N.
Sandhu, S.
Chi, K. N.
Sartor, O.
Agarwal, N.
Olmos, D.
Thiery-Vuillemin, A.
Twardowski, P.
Mehra, N.
Goessl, C.
Kang, J.
Burgents, J.
Wu, W.
Kohlmann, A.
Adelman, C. A.
Hussain, M.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (22) : 2091 - 2102
[7] Gillessen S, 2023, 2023 GEN GU AM SOC C
[8] Genomic and phenotypic heterogeneity in prostate cancer
Haffner, Michael C.
Zwart, Wilbert
Roudier, Martine P.
True, Lawrence D.
Nelson, William G.
Epstein, Jonathan, I
De Marzo, Angelo M.
Nelson, Peter S.
Yegnasubramanian, Srinivasan
[J]. NATURE REVIEWS UROLOGY, 2021, 18 (02) : 79 - 92
[9] Practical Utility of Liquid Biopsies for Evaluating Genomic Alterations in Castration-Resistant Prostate Cancer
Jeong, Seung-Hwan
Kyung, Dongsoo
Yuk, Hyeong Dong
Jeong, Chang Wook
Lee, Wookjae
Yoon, Jung-Ki
Kim, Hwang-Phill
Bang, Duhee
Kim, Tae-You
Lim, Yoojoo
Kwak, Cheol
[J]. CANCERS, 2023, 15 (10)
[10] DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J.
Carreira, S.
Sandhu, S.
Miranda, S.
Mossop, H.
Perez-Lopez, R.
Rodrigues, D. Nava
Robinson, D.
Omlin, A.
Tunariu, N.
Boysen, G.
Porta, N.
Flohr, P.
Gillman, A.
Figueiredo, I.
Paulding, C.
Seed, G.
Jain, S.
Ralph, C.
Protheroe, A.
Hussain, S.
Jones, R.
Elliott, T.
McGovern, U.
Bianchini, D.
Goodall, J.
Zafeiriou, Z.
Williamson, C. T.
Ferraldeschi, R.
Riisnaes, R.
Ebbs, B.
Fowler, G.
Roda, D.
Yuan, W.
Wu, Y. -M.
Cao, X.
Brough, R.
Pemberton, H.
A'Hern, R.
Swain, A.
Kunju, L. P.
Eeles, R.
Attard, G.
Lord, C. J.
Ashworth, A.
Rubin, M. A.
Knudsen, K. E.
Feng, F. Y.
Chinnaiyan, A. M.
Hall, E.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (18) : 1697 - 1708

← 1 →